Semaglutide, an active ingredient found in popular weight loss drugs Ozempic and Wegovy, has been found to have a range of adverse health issues for users, including serious stomach conditions like paralysis and gastroparesis in diabetics, according to a new study.
The drugs work by mimicking a hormone, Glucagon-like peptide 1 (GLP-1), which makes users feel satiated after eating. Consumed for weight maintenance, it regulates appetite, and delays gastric emptying and gut motility in humans.
